Neuropro Technologies, Inc.
USPTO PatentsView assignee record - 28 granted patents across 2 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61F (Filters Implantable Into Blood VESSELS; PROSTHESES; Devices Providing Patency TO, OR Preventing Collapsing OF, Tubular Structures OF THE Body, e.g. STENTS; Orthopaedic, Nursing OR Contraceptive Device).
The verdict
According to USPTO PatentsView, Neuropro ranks #11,020 of 49,997 tracked US assignees by granted-patent volume, with 28 patents across 2 technology areas.
- #11,020
- of 49,997 US assignees by volume
- 48th percentile
- by Innovation Score (34.7/100)
- 22.3
- avg claims per patent
- +27%
- grant velocity, last 5 yrs
USPTO PatentsView assignee plate
Corpus R11020 · US Corporation #11,020 · 28 grants
GRANTS-SMALL · UPPER-Q · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-DENSE · TYPE-USCORP · VEL-UP · BOOK-FULL
- GRANTS-SMALL 28 grants
- UPPER-Q #11,020/49,997
- PHOTO-FINISH Nagase ChemteX
- CPC-NARROW A61F · 2 areas
- INNOV-THIN 34.7/100
- CLAIMS-DENSE 22.3 claims/avg
- TYPE-USCORP US Corporation
- VEL-UP +27% vel
- BOOK-FULL 10/10 fields
Nearest grant-volume peer: Nagase ChemteX Corporation (±0 grants)
Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.
How Neuropro’s 34.7 Innovation Score adds up
The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.
Innovation-score neighbourhood around Neuropro
Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.
- Qualcomm Incorporated · highest
Qualcomm Incorporated · highest
85 score
- Idex ASA · near
Idex ASA · near
35 score
- Integrated Medical… · near
Integrated Medical… · near
35 score
- Neuropro · this assignee
Neuropro · this assignee
35 score
- Smart Modular · near
Smart Modular · near
35 score
- Satori Worldwide · near
Satori Worldwide · near
35 score
- 3D Lighting… · lowest 7
3D Lighting… · lowest
7 score
What this shows Neuropro's Innovation Score is 34.7/100 (48th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.
Does more volume mean deeper claims for Neuropro?
Each dot is one of Neuropro’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Neuropro’s own 22.3 claims/patent is ABOVE the 13.7 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.
Where Neuropro's grants concentrate
Neuropro Technologies, Inc. is a focused PatentsView assignee: 2 CPC subclasses with 96.4% of grants classified under A61F (Filters Implantable Into Blood VESSELS; PROSTHESES; Devices Providing Patency TO, OR Preventing Collapsing OF, Tubular Structures OF THE Body, e.g. STENTS; Orthopaedic, Nursing OR Contraceptive Device). Peak complete grant year is 2018 (5 grants) versus a trough of 1 in 2015. By volume, Neuropro sits between Nutramax Laboratories, Inc. and Ondal Medical Systems GMBH.
Neuropro's three-year grant acceleration
Neuropro Technologies, Inc. shows 7 grants in 2022–2024 against only 10 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.
Who files at Neuropro's volume?
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
- Nutramax Laborato…
Nutramax Laboratories, Inc.
28 patents
- Nagase Chemtex
Nagase ChemteX Corporation
28 patents
- Nemoto Kyorindo
Nemoto Kyorindo Co., Ltd.
28 patents
- Neochord
NeoChord, Inc.
28 patents
- Next Silicon
Next Silicon Ltd
28 patents
- Nucana
NuCana plc
28 patents
- O2 Partners
O2 Partners, LLC
28 patents
- Ondal Medical Sys…
Ondal Medical Systems GMBH
28 patents
- Neuropro ◀
Neuropro Technologies, Inc.
28 patents
What this shows Neuropro holds 28 patents at rank #11,024, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Companies ranked near Neuropro
By rank, the assignees closest to #11,024 in granted patent volume.
- Nutramax Laboratories, Inc. #11,020 · 28 patents
- Nagase ChemteX Corporation #11,021 · 28 patents
- Nemoto Kyorindo Co., Ltd. #11,022 · 28 patents
- NeoChord, Inc. #11,023 · 28 patents
- Next Silicon Ltd #11,025 · 28 patents
- NuCana plc #11,026 · 28 patents
- O2 Partners, LLC #11,027 · 28 patents
- Ondal Medical Systems GMBH #11,028 · 28 patents
Leaders in A61F (Filters Implantable Into Blood Vessels)
Other assignees with the most granted patents in Neuropro's primary technology class.
- The Procter & Gamble Company 1,426 in class
- Boston Scientific Scimed, Inc. 1,101 in class
- Edwards Lifesciences Corporation 1,101 in class
- DePuy Synthes Products, Inc. 851 in class
- Globus Medical, Inc. 752 in class
- Cook Medical Technologies LLC 700 in class
- Smith & Nephew, Inc. 541 in class
- Covidien LP 528 in class
Assignees with similar portfolio profiles
Two PlainPatent-derived peer sets for Neuropro, neither rank-band nor same-CPC leaders (those blocks stay above). In A61F (Filters Implantable Into Blood Vessels), Neuropro ranks #238 of 3,082 assignees by patent count in that subclass.
Similar innovation score
Nearest assignees by Innovation Score (35 here).
Neuropro's Innovation Score vs. every tracked assignee
Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)
35 48th percentile higher than 48% of 49,997 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2015 | 1 | 3.6% |
| 2016 | 1 | 3.6% |
| 2017 | 1 | 3.6% |
| 2018 | 5 | 17.9% |
| 2019 | 3 | 10.7% |
| 2020 | 5 | 17.9% |
| 2021 | 2 | 7.1% |
| 2022 | 5 | 17.9% |
| 2023 | 1 | 3.6% |
| 2024 | 1 | 3.6% |
| 2025partial year | 3 | 10.7% |
Which technologies does Neuropro Technologies, Inc. patent most?
Top 2 of 2 technology areas
Data Source
USPTO PatentsView, US granted patents 2015–2025
What to do with this data
Neuropro Technologies, Inc.'s patent record in context - here's where to go next.
- Neuropro Technologies, Inc.'s lead technology class is A61F (Filters Implantable Into Blood VESSELS; PROSTHESES; Devices Providing Patency TO, OR Preventing Collapsing OF, Tubular Structures OF THE Body, e.g. STENTS; Orthopaedic, Nursing OR Contraceptive Device), 96.4% of its portfolio - see every assignee active in that class. Explore A61F
- Ranked #11,020 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
- Compare Neuropro Technologies, Inc. against Nutramax Laboratories, Inc., an assignee filing at a similar volume. Compare portfolios
- Innovation Score of 34.7/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated
Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.